Tocilizumab for the treatment of large-vessel vasculitis (giant cell arteritis, Takayasu arteritis) and polymyalgia rheumatica

Arthritis Care and Research

Volumn 64, Issue 11, 2012, Pages 1720-1729

  Unizony, S ^a   Arias Urdaneta, L ^a   Miloslavsky, E ^a   Arvikar, S ^a   Khosroshahi, A ^a   Keroack, B ^b,c   Stone, J R ^a   Stone, J H ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b Rheumatology Associates   (United States)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADALIMUMAB; ASPARTATE AMINOTRANSFERASE; AZATHIOPRINE; BIOLOGICAL MARKER; CYCLOPHOSPHAMIDE; ETANERCEPT; GLUCOCORTICOID; INFLIXIMAB; INTERLEUKIN 6; METHOTREXATE; PREDNISONE; TOCILIZUMAB;

ADRENAL INSUFFICIENCY; ADULT; AGED; AORTA ARCH SYNDROME; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; AUTOPSY; BIOPSY; BIOPSY TECHNIQUE; BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL FEATURE; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; DISEASE COURSE; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FOLLOW UP; GIANT CELL ARTERITIS; HUMAN; HYPERTRANSAMINASEMIA; INFLAMMATION; MALE; NEUTROPENIA; OUTCOME ASSESSMENT; POSITRON EMISSION TOMOGRAPHY; REMISSION; RHEUMATIC POLYMYALGIA; SEROLOGY; SIDE EFFECT; TEMPORAL ARTERY BIOPSY; TREATMENT DURATION; TREATMENT FAILURE;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; DOSE-RESPONSE RELATIONSHIP, DRUG; FOLLOW-UP STUDIES; GIANT CELL ARTERITIS; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MIDDLE AGED; POLYMYALGIA RHEUMATICA; PREDNISONE; RECEPTORS, INTERLEUKIN-6; RETROSPECTIVE STUDIES; TAKAYASU ARTERITIS; TREATMENT OUTCOME;

EID: 84868259701     PISSN: 2151464X     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.21750     Document Type: Article

References (55)

1. Mukhtyar C, Guillevin L, Cid MC, Dasgupta B, de Groot K, Gross W, et al. EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis 2009; 68: 318-23.
2. Hatz HJ, Helmke K,. Polymyalgia rheumatica and giant cell arteritis; diagnosis and side effects of low-dose long-term glucocorticoid therapy. Z Rheumatol 1992; 51: 213-21. In German.
3. Maksimowicz-McKinnon K, Clark TM, Hoffman GS,. Limitations of therapy and a guarded prognosis in an American cohort of Takayasu arteritis patients. Arthritis Rheum 2007; 56: 1000-9.
4. Proven A, Gabriel SE, Orces C, O'Fallon WM, Hunder GG,. Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes. Arthritis Rheum 2003; 49: 703-8.
5. Kerr GS, Hallahan CW, Giordano J, Leavitt RY, Fauci AS, Rottem M, et al. Takayasu arteritis. Ann Intern Med 1994; 120: 919-29.
6. Jover JA, Hernandez-Garcia C, Morado IC, Vargas E, Banares A, Fernandez-Gutierrez B,. Combined treatment of giant-cell arteritis with methotrexate and prednisone: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 2001; 134: 106-14.
7. Hoffman GS, Cid MC, Hellmann DB, Guillevin L, Stone JH, Schousboe J, et al. A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis. Arthritis Rheum 2002; 46: 1309-18.
8. Spiera RF, Mitnick HJ, Kupersmith M, Richmond M, Spiera H, Peterson MG, et al. A prospective, double-blind, randomized, placebo controlled trial of methotrexate in the treatment of giant cell arteritis (GCA). Clin Exp Rheumatol 2001; 19: 495-501.
9. Jover JA, Hernandez-Garcia C, Morado IC, Vargas E, Banares A, Fernandez-Gutierrez B,. Disparate results in studies of methotrexate plus corticosteroids in the treatment of giant cell arteritis: comment on the article by Hoffman et al [letter]. Arthritis Rheum 2003; 48: 1158-9.
10. Shelhamer JH, Volkman DJ, Parrillo JE, Lawley TJ, Johnston MR, Fauci AS,. Takayasu's arteritis and its therapy. Ann Intern Med 1985; 103: 121-6.
11. Goel R, Danda D, Mathew J, Edwin N,. Mycophenolate mofetil in Takayasu's arteritis. Clin Rheumatol 2010; 29: 329-32.
12. Schaufelberger C, Andersson R, Nordborg E,. No additive effect of cyclosporin A compared with glucocorticoid treatment alone in giant cell arteritis: results of an open, controlled, randomized study [letter]. Br J Rheumatol 1998; 37: 464-5.
13. De Vita S, Tavoni A, Jeracitano G, Gemignani G, Dolcher MP, Bombardieri S,. Treatment of giant cell arteritis with cyclophosphamide pulses. J Intern Med 1992; 232: 373-5.
14. De Silva M, Hazleman BL,. Azathioprine in giant cell arteritis/ polymyalgia rheumatica: a double-blind study. Ann Rheum Dis 1986; 45: 136-8.
15. Mahr AD, Jover JA, Spiera RF, Hernandez-Garcia C, Fernandez-Gutierrez B, LaValley MP, et al. Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis. Arthritis Rheum 2007; 56: 2789-97.
16. Hoffman GS, Cid MC, Rendt-Zagar KE, Merkel PA, Weyand CM, Stone JH, et al. Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial. Ann Intern Med 2007; 146: 621-30.
17. Salvarani C, Macchioni P, Manzini C, Paolazzi G, Trotta A, Manganelli P, et al. Infliximab plus prednisone or placebo plus prednisone for the initial treatment of polymyalgia rheumatica: a randomized trial. Ann Intern Med 2007; 146: 631-9.
18. Hoffman GS, Leavitt RY, Kerr GS, Rottem M, Sneller MC, Fauci AS,. Treatment of glucocorticoid-resistant or relapsing Takayasu arteritis with methotrexate. Arthritis Rheum 1994; 37: 578-82.
19. Molloy ES, Langford CA, Clark TM, Gota CE, Hoffman GS,. Anti-tumour necrosis factor therapy in patients with refractory Takayasu arteritis: long-term follow-up. Ann Rheum Dis 2008; 67: 1567-9.
20. Naka T, Nishimoto N, Kishimoto T,. The paradigm of IL-6: from basic science to medicine. Arthritis Res 2002; 4 Suppl 3: S233-42.
21. Garcia-Martinez A, Hernandez-Rodriguez J, Espigol-Frigole G, Prieto-Gonzalez S, Butjosa M, Segarra M, et al. Clinical relevance of persistently elevated circulating cytokines (tumor necrosis factor α and interleukin-6) in the long-term followup of patients with giant cell arteritis. Arthritis Care Res (Hoboken) 2010; 62: 835-41.
22. Weyand CM, Fulbright JW, Hunder GG, Evans JM, Goronzy JJ,. Treatment of giant cell arteritis: interleukin-6 as a biologic marker of disease activity. Arthritis Rheum 2000; 43: 1041-8.
23. Noris M, Daina E, Gamba S, Bonazzola S, Remuzzi G,. Interleukin-6 and RANTES in Takayasu arteritis: a guide for therapeutic decisions? Circulation 1999; 100: 55-60.
24. Martinez-Taboada VM, Alvarez L, RuizSoto M, Marin-Vidalled MJ, Lopez-Hoyos M,. Giant cell arteritis and polymyalgia rheumatica: role of cytokines in the pathogenesis and implications for treatment. Cytokine 2008; 44: 207-20.
25. Singh JA, Beg S, Lopez-Olivo MA,. Tocilizumab for rheumatoid arthritis: a Cochrane systematic review. J Rheumatol 2011; 38: 10-20.
26. Yokota S, Imagawa T, Mori M, Miyamae T, Aihara Y, Takei S, et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet 2008; 371: 998-1006.
27. Ito H, Takazoe M, Fukuda Y, Hibi T, Kusugami K, Andoh A, et al. A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease. Gastroenterology 2004; 126: 989-97.
28. Thonhofer R, Hiller M, Just H, Trummer M, Siegel C, Dejaco C,. Treatment of refractory adult-onset Still's disease with tocilizumab: report of two cases and review of the literature. Rheumatol Int 2011; 31: 1653-6.
29. Matsuyama M, Suzuki T, Tsuboi H, Ito S, Mamura M, Goto D, et al. Anti-interleukin-6 receptor antibody (tocilizumab) treatment of multicentric Castleman's disease. Intern Med 2007; 46: 771-4.
30. Hunder GG, Bloch DA, Michel BA, Stevens MB, Arend WP, Calabrese LH, et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum 1990; 33: 1122-8.
31. Arend WP, Michel BA, Bloch DA, Hunder GG, Calabrese LH, Edworthy SM, et al. The American College of Rheumatology 1990 criteria for the classification of Takayasu arteritis. Arthritis Rheum 1990; 33: 1129-34.
32. Jones JG, Hazleman BL,. Prognosis and management of polymyalgia rheumatica. Ann Rheum Dis 1981; 40: 1-5.
33. Seitz M, Reichenbach S, Bonel HM, Adler S, Wermelinger F, Villiger PM,. Rapid induction of remission in large vessel vasculitis by IL-6 blockade: a case series. Swiss Med Wkly 2011; 141: w13156.
34. Beyer C, Axmann R, Sahinbegovic E, Distler JH, Manger B, Schett G, et al. Anti-interleukin 6 receptor therapy as rescue treatment for giant cell arteritis [letter]. Ann Rheum Dis 2011; 70: 1874-5.
35. Hagihara K, Kawase I, Tanaka T, Kishimoto T,. Tocilizumab ameliorates clinical symptoms in polymyalgia rheumatica [letter]. J Rheumatol 2010; 37: 1075-6.
36. Nishimoto N, Nakahara H, Yoshio-Hoshino N, Mima T,. Successful treatment of a patient with Takayasu arteritis using a humanized anti-interleukin-6 receptor antibody. Arthritis Rheum 2008; 58: 1197-200.
37. Sciascia S, Rossi D, Roccatello D,. Interleukin 6 blockade as steroid-sparing treatment for 2 patients with giant cell arteritis [letter]. J Rheumatol 2011; 38: 2080-1.
38. Salvarani C, Magnani L, Catanoso M, Pipitone N, Versari A, Dardani L, et al. Tocilizumab: a novel therapy for patients with large-vessel vasculitis. Rheumatology (Oxford) 2012; 51: 151-6.
39. Deng J, Younge BR, Olshen RA, Goronzy JJ, Weyand CM,. Th17 and Th1 T-cell responses in giant cell arteritis. Circulation 2010; 121: 906-15.
40. Terrier B, Geri G, Chaara W, Allenbach Y, Rosenzwajg M, Costedoat-Chalumeau N, et al. Interleukin-21 modulates Th1 and Th17 responses in giant cell arteritis. Arthritis Rheum 2012; 64: 2001-11.
41. Ma-Krupa W, Jeon MS, Spoerl S, Tedder TF, Goronzy JJ, Weyand CM,. Activation of arterial wall dendritic cells and breakdown of self-tolerance in giant cell arteritis. J Exp Med 2004; 199: 173-83.
42. Fujimoto M, Serada S, Mihara M, Uchiyama Y, Yoshida H, Koike N, et al. Interleukin-6 blockade suppresses autoimmune arthritis in mice by the inhibition of inflammatory Th17 responses. Arthritis Rheum 2008; 58: 3710-9.
43. Miossec P, Korn T, Kuchroo VK,. Interleukin-17 and type 17 helper T cells. N Engl J Med 2009; 361: 888-98.
44. O'Shea JJ, Paul WE,. Mechanisms underlying lineage commitment and plasticity of helper CD4+ T cells. Science 2010; 327: 1098-102.
45. Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006; 441: 235-8.
46. Haruta H, Ohguro N, Fujimoto M, Hohki S, Terabe F, Serada S, et al. Blockade of interleukin-6 signaling suppresses not only Th17 but also interphotoreceptor retinoid binding protein-specific Th1 by promoting regulatory T cells in experimental autoimmune uveoretinitis. Invest Ophthalmol Vis Sci 2011; 52: 3264-71.
47. Korn T, Mitsdoerffer M, Croxford AL, Awasthi A, Dardalhon VA, Galileos G, et al. IL-6 controls Th17 immunity in vivo by inhibiting the conversion of conventional T cells into FoxP3+ regulatory T cells. Proc Natl Acad Sci U S A 2008; 105: 18460-5.
48. Park MC, Lee SW, Park YB, Lee SK,. Serum cytokine profiles and their correlations with disease activity in Takayasu's arteritis. Rheumatology (Oxford) 2006; 45: 545-8.
49. Seko Y, Sato O, Takagi A, Tada Y, Matsuo H, Yagita H, et al. Restricted usage of T-cell receptor Vα-Vβ genes in infiltrating cells in aortic tissue of patients with Takayasu's arteritis. Circulation 1996; 93: 1788-90.
50. Suzuki M, Hashizume M, Yoshida H, Mihara M,. Anti-inflammatory mechanism of tocilizumab, a humanized anti-IL-6R antibody: effect on the expression of chemokine and adhesion molecule. Rheumatol Int 2010; 30: 309-15.
51. Nishimoto N, Terao K, Mima T, Nakahara H, Takagi N, Kakehi T,. Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood 2008; 112: 3959-64.
52. Uchiyama Y, Yoshida H, Koike N, Hayakawa N, Sugita A, Nishimura T, et al. Anti-IL-6 receptor antibody increases blood IL-6 level via the blockade of IL-6 clearance, but not via the induction of IL-6 production. Int Immunopharmacol 2008; 8: 1595-601.
53. Nishimoto N,. Drug free remission after cessation of tocilizumab (actemra) monotherapy (DREAM Study) [abstract]. Arthritis Rheum 2010; 62 Suppl: S750.
54. Rojo-Leyva F, Ratliff NB, Cosgrove DM 3rd, Hoffman GS,. Study of 52 patients with idiopathic aortitis from a cohort of 1,204 surgical cases. Arthritis Rheum 2000; 43: 901-7.
55. Narvaez J, Bernad B, Roig-Vilaseca D, Garcia-Gomez C, Gomez-Vaquero C, Juanola X, et al. Influence of previous corticosteroid therapy on temporal artery biopsy yield in giant cell arteritis. Semin Arthritis Rheum 2007; 37: 13-9.